SLAMUNITI Trademark

Trademark Overview


On Wednesday, February 16, 2022, a trademark application was filed for SLAMUNITI with the United States Patent and Trademark Office. The USPTO has given the SLAMUNITI trademark a serial number of 97269673. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Monday, May 20, 2024. This trademark is owned by Bristol-Myers Squibb Company. The SLAMUNITI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
slamuniti

General Information


Serial Number97269673
Word MarkSLAMUNITI
Filing DateWednesday, February 16, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateMonday, May 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 11, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 22, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Wednesday, March 8, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, February 19, 2022NEW APPLICATION ENTERED
Tuesday, February 22, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, September 26, 2022ASSIGNED TO EXAMINER
Thursday, September 29, 2022PRIORITY ACTION WRITTEN
Thursday, September 29, 2022PRIORITY ACTION E-MAILED
Thursday, September 29, 2022NOTIFICATION OF PRIORITY ACTION E-MAILED
Wednesday, March 8, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 8, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 9, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 11, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 6, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 22, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 22, 2023SOU EXTENSION 1 FILED
Wednesday, November 22, 2023SOU EXTENSION 1 GRANTED
Friday, November 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 20, 2024SOU EXTENSION 2 FILED
Monday, May 20, 2024SOU EXTENSION 2 GRANTED
Monday, May 20, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, May 21, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED